Short-term outcomes of sodium glucose co-transporter 2 inhibitors on left ventricular diastolic function in diabetic patients presented by acute heart failure with preserved ejection fraction

Background Focusing on the short-term effects of sodium glucose co-transporter 2 (SGLT2) inhibitors, this study examines their impact on left ventricular diastolic function in diabetic patients with acute heart failure and preserved ejection fraction (HFpEF). By lowering blood sugar, blood pressure, and aiding in weight loss, SGLT2 inhibitors are being evaluated for their potential to improve both diabetes management and heart function in individuals with HF. Aim The purpose of this study was to evaluate the short-term impact of SGLT2 inhibitors on diastolic function in diabetic patients with acute HFpEF. Patients and methods A randomized study enrolled 60 adults with type 2 diabetes mellitus and echocardiographically confirmed HFpEF. Patients were divided into two groups: group 1 received SGLT2 inhibitors alongside standard HF therapy, and group 2 received standard therapy alone. Results Clinical outcome studied at 3 months with notification of any adverse events during this period. SGLT2I user group showed significant impact on clinical outcome with lower adverse events as compared with nonusers of SGLT2I 3 months follow-up (OR=0.141, P =0.004). Higher left atrial (LA) volume was significantly predictor of negative outcome ( P =0.018). Kidney function, blood pressure, heart rate, BNP, glycated hemoglobin, left ventricular ejection fraction, and the (E/e) ratio, in contrast, did not show any significant prediction. Patients who received SGLT2i showed significantly better results in left ventricular ejection fraction, LA volume, E/A ratio, and E/e ratio after 3 months Conclusions Using SGLT2I had better clinical outcomes and fewer adverse events and increased LA volume was correlated with an increased likelihood of unfavorable results.